Cargando…

Clinical Outcomes in AchR Antibody-Positive Myasthenia Gravis: Where Does Rituximab Stand in the Current Times?

Detalles Bibliográficos
Autor principal:	Dhamne, Megha Chetan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645217/ https://www.ncbi.nlm.nih.gov/pubmed/37970317 http://dx.doi.org/10.4103/aian.aian_516_23

Ejemplares similares

Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020)

Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)

Oral Microbiota Profile in a Group of Anti-AChR Antibody–Positive Myasthenia Gravis Patients
por: Huang, Chao, et al.
Publicado: (2022)

Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country
por: Mathew, Thomas, et al.
Publicado: (2021)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015)

Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis
por: Seok, Jo Woon, et al.
Publicado: (2023)

The Clinical Outcome in AChR-Positive Generalized Myasthenia Gravis: A Retrospective Observational Study
por: Ojha, Pawan T., et al.
Publicado: (2023)

A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis
por: Cai, Yu, et al.
Publicado: (2021)

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient
por: Saxena, Abhishek, et al.
Publicado: (2017)

SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
por: Huda, Saif, et al.
Publicado: (2019)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
por: Zhao, Rui, et al.
Publicado: (2021)

Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody
por: Chen, Yuping, et al.
Publicado: (2022)

Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
por: Spagni, Gregorio, et al.
Publicado: (2022)

Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
por: Kordas, Gregory, et al.
Publicado: (2014)

Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, Jae‐Yun, et al.
Publicado: (2016)

Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature
por: Ge, XiuShan, et al.
Publicado: (2022)

Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
por: Lekova, Eleonora, et al.
Publicado: (2022)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
Publicado: (2015)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
Publicado: (2015)

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
por: Lupica, Antonino, et al.
Publicado: (2022)

Autoantibody of NRIP, a novel AChR‐interacting protein, plays a detrimental role in myasthenia gravis
por: Tsai, Li‐Kai, et al.
Publicado: (2021)

FoxP3(−) Tr1 Cell in Generalized Myasthenia Gravis and Its Relationship With the Anti-AChR Antibody and Immunomodulatory Cytokines
por: Meng, Huanyu, et al.
Publicado: (2021)

The Association of PTPN22 R620W Polymorphism Is Stronger with Late-Onset AChR-Myasthenia Gravis in Turkey
por: Kaya, Gizem A., et al.
Publicado: (2014)

A Patient with Fulminant Myasthenia Gravis Is Seropositive for Both AChR and LRP4 Antibodies, Complicated by Autoimmune Polyglandular Syndrome Type 3
por: Inoue, Hiroyasu, et al.
Publicado: (2020)

ACHR-Positive Generalized Myasthenia Gravis: The Old is Gold and the New Is for us to Explore
por: Hiew, Fu Liong
Publicado: (2023)

Myasthenia Gravis With Thymoma, Manifesting as AChR-Ab-Positive, Distinct Bulbar Palsy Accompanied by Dysgeusia: A Case Series and Review of Literature
por: Zhu, Kai, et al.
Publicado: (2018)

Diffuse Gonococcal Infection (DGI) in a Patient with Treatment-Refractory Acetylcholine Receptor Antibody-Positive (AChR+) Generalized Myasthenia Gravis (gMG) Treated with Eculizumab
por: Katyal, Nakul, et al.
Publicado: (2021)

Association of HLA-DQB1∗05:02 and DRB1∗16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis
por: Testi, Manuela, et al.
Publicado: (2012)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
por: Waheed, Waqar, et al.
Publicado: (2022)

Immunoblot analysis of antiAChR antibodies in myasthenia gravis
por: Mantegazza, R., et al.
Publicado: (1988)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
Publicado: (2022)

Rituximab treatment in myasthenia gravis
por: Vesperinas-Castro, Ana, et al.
Publicado: (2023)

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis
por: Huan, Xiao, et al.
Publicado: (2022)

Slow‐channel myasthenia due to novel mutation in M2 domain of AChR delta subunit
por: Shen, Xin‐Ming, et al.
Publicado: (2019)

Impaired gating of γ‐ and ε‐AChR respectively causes Escobar syndrome and fast‐channel myasthenia
por: Shen, Xin‐Ming, et al.
Publicado: (2023)

The Expression Pattern and Regulatory Mechanism of the G0/G1 Switch Gene 2 (G0S2) in the Pathogenesis and Treatment of AChR Myasthenia Gravis (MG)
por: Xu, Liqun, et al.
Publicado: (2020)

Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
por: Verma, Neha, et al.
Publicado: (2021)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Clinical application of clustered-AChR for the detection of SNMG
por: Zhao, Guang, et al.
Publicado: (2015)

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s8bfn0u0o7s9f84os58nhu9g9i